<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276597</url>
  </required_header>
  <id_info>
    <org_study_id>143631</org_study_id>
    <nct_id>NCT04276597</nct_id>
  </id_info>
  <brief_title>Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.</brief_title>
  <acronym>PUTNET</acronym>
  <official_title>A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Excel Diagnostics and Nuclear Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Excel Diagnostics and Nuclear Oncology Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin&#xD;
      receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus&#xD;
      neuroendocrine tumors or any other non-.GEP-NET.&#xD;
&#xD;
      The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at&#xD;
      8+/- 1-week intervals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the overall response rate</measure>
    <time_frame>12 monts</time_frame>
    <description>determined using standard of care scans NETSPOT PET/CT, Octreoscan SPECT/CT, MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (rPFS) in subjects receiving 4 cycles of therapy Monitoring of the changes in quality of life (QOL) through assessment of ECOG performance status and a QOL subject questionnaire.</measure>
    <time_frame>12 months</time_frame>
    <description>determined using standard of care scans NETSPOT PET/CT, Octreoscan SPECT/CT, MRI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Neuroendocrine Neoplasm</condition>
  <condition>Pheochromocytoma</condition>
  <condition>Paraganglioma</condition>
  <condition>Thymus Carcinoid</condition>
  <condition>Unknown Primary Tumors</condition>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Neuroendocrine Skin Carcinoma</condition>
  <condition>Neuroendocrine Breast Tumor</condition>
  <condition>Neuroendocrine Carcinoma Metastatic</condition>
  <condition>Neuroendocrine Neoplasm of Ovary</condition>
  <arm_group>
    <arm_group_label>Lu177 DOTATOC treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 doses of 200mCi 177Lu- DOTATOC PRRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-DOTATOC</intervention_name>
    <description>177Lu labeled somatostatin receptors targeting ligand</description>
    <arm_group_label>Lu177 DOTATOC treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Subjects of either sex, aged ≥18 years.&#xD;
&#xD;
          -  ECOG status 0-2.&#xD;
&#xD;
          -  Life-expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Histologically/cytologically confirmed diagnosis of SSTR (+) neuroendocrine tumors of&#xD;
             the lung, Pheochromocytoma, Paraganglioma, thymus, and unknown primary, unresectable&#xD;
             or metastatic.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1, on CT/MRI scans, defined as at least 1 lesion with&#xD;
             ≥ 1 cm in longest diameter (lymph nodes along short axis &gt;15 mm).&#xD;
&#xD;
          -  Appropriate diagnostic imaging studies, at the discretion of the P.I. including but&#xD;
             not limited to CT, MRI , 18F-FDG PET/CT, NAF PET/CT bone scan, ultrasound, etc. of the&#xD;
             tumor region or suspected area within the 4 weeks of dosing day.&#xD;
&#xD;
          -  Somatostatin receptor positive (SSTR+) disease, as evidenced by available FDA,&#xD;
             commercially of IND approved SSTR imaging (SRI), within 4 weeks prior to the first&#xD;
             cycle&#xD;
&#xD;
          -  Recent blood test results (within 2weeks pre-dose) as follows:&#xD;
&#xD;
          -  Sufficient bone marrow capacity as defined by WBC ≥2,500/µl and WBC≥2,000/mm3 for&#xD;
             subsequent cycles; platelets ≥ 100,000 (100 * 103/mm3) for the first treatment and&#xD;
             ≥75,000 for the subsequent therapies, Hgb ≥8.9 g/dl for the first treatment and 8.0&#xD;
             g/dl for the subsequent therapies, ANC ≥1500/mm3 for the first treatment and ≥1000/&#xD;
             mm3; for the subsequent therapies.&#xD;
&#xD;
          -  ALT, AST values ≤3 times ULN&#xD;
&#xD;
          -  Bilirubin: ≤3 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 150 µmol/liter or 1.7 mg/dl&#xD;
&#xD;
          -  Negative pregnancy test in women capable of child-bearing within 48 hours of IMP&#xD;
             administration.&#xD;
&#xD;
          -  Serum albumin &gt; 3.0g/L (&lt;3 g/L may be acceptable at the discretion of investigator, if&#xD;
             PT, PTT, and INR are within normal range)&#xD;
&#xD;
          -  All available FDA-approved therapies for which the subject is eligible have been&#xD;
             exhausted (with the exception of PRRT), unless available therapies are refused by the&#xD;
             subject (with the exception of somatostatin analogue, octreotide, and somatuline).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any of the excipients of Lu-177 DOTATOC.&#xD;
&#xD;
          -  Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28&#xD;
             days) and Sandostatin® (within 1 day) prior to treatment.&#xD;
&#xD;
          -  Subjects with unusual hematological parameters, including an increased MCV (&gt;105fL),&#xD;
             and especially in those who had previous chemotherapy, the advice of a hematologist&#xD;
             should be sought for adequate further work-up&#xD;
&#xD;
          -  Any subject who is taking concomitant medications that decrease renal function (such&#xD;
             as aminoglycoside antibiotics).&#xD;
&#xD;
          -  Female subjects who are pregnant, lactating or women of childbearing potential not&#xD;
             willing to practice effective contraceptive techniques during the study period and for&#xD;
             67 days (more than 10 half-lives of 177Lu after the last treatment, or male subjects&#xD;
             who have female partners of childbearing potential not willing to practice abstinence&#xD;
             or effective contraception, during the study period and for 67 days after the last&#xD;
             treatment.&#xD;
&#xD;
          -  Current somatic or psychiatric disease/condition that may interfere with the&#xD;
             objectives and assessments of the study.&#xD;
&#xD;
          -  Indication for surgical lesion removal with curative potential&#xD;
&#xD;
          -  Planned (for the period of study participation): chemotherapy, immunotherapy,&#xD;
             radiation therapy (unless regional for pain relief) chemo-embolization, bland&#xD;
             embolization, radio-embolization, treatment with cyclosporine-A.&#xD;
&#xD;
          -  Known brain metastases; unless these metastases have been treated and stabilized 6&#xD;
             months prior to enrolment&#xD;
&#xD;
          -  Completion of: (1) cytotoxic chemotherapy for less than 6 weeks; (2) a biological&#xD;
             agent for less than 5 half-lives; and (3) radiation therapy (except regional for pain&#xD;
             relief) for less than 6 weeks prior to study enrolment,&#xD;
&#xD;
          -  Uncontrolled congestive heart failure; subjects suspected of having this condition&#xD;
             need to show ejection fraction of &gt; 35% as determined by MUGA scan.&#xD;
&#xD;
          -  Glomerular Filtration Rate (GFR) &lt; 35 mL/min&#xD;
&#xD;
          -  Subjects with prior peptide receptor radionuclide therapy (PPRT).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebrahim Delpassand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Excel Diagnostics and Nuclear Oncology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodolfo Nunez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Excel Diagnostics and Nuclear Oncology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Afshin Shafie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Excel Diagnostics and Nuclear Oncology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman Gaber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Excel Diagnostics and Nuclear Oncology Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Cork</last_name>
    <phone>713-781-6200</phone>
    <phone_ext>3203</phone_ext>
    <email>scork@exceldiagnostics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rouzbeh Esfandiari, MD</last_name>
    <phone>713-781-6200</phone>
    <phone_ext>3279</phone_ext>
    <email>resfandiari@exceldiagnostics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Excel Diagnostics and Nuclear Oncology Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Cork</last_name>
      <phone>713-341-3203</phone>
      <email>scork@exceldiagnostics.com</email>
    </contact>
    <contact_backup>
      <last_name>Izabela Tworowska, PhD</last_name>
      <phone>713-590-0601</phone>
      <email>itworowska@radiomedix.com</email>
    </contact_backup>
    <investigator>
      <last_name>Afshin Shafie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodolfo Nunez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ebrahim Delpassand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroendocrine tumors</keyword>
  <keyword>Thymus neuroendocrine</keyword>
  <keyword>Unknown Primary</keyword>
  <keyword>Paraganglioma</keyword>
  <keyword>Pheochromocytoma</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Any other non-.GEP-NET</keyword>
  <keyword>NET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

